Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 6/20 | 0.40 |
| ▸ | CDK2 | P24941 | 5/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.33 |
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.33 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.33 |
| ▸ | CDK7 | P50613 | 2/20 | 0.32 |
| ▸ | CCNH | P51946 | 2/20 | 0.32 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | GPR39 | O43194 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13146206 | 0.92 | GSK3B (0.51) | GSK3BCHEK1CDK2CCNA2CCNA1 | |
| SCHEMBL12953011 | 0.89 | GSK3B (0.63) | GSK3BCHEK1CDK2CCNA2CCNA1 | |
| SCHEMBL13305061 | 0.85 | GSK3B (0.49) | GSK3BCHEK1CDK2CCNA2CCNA1 | |
| SCHEMBL12952905 | 0.81 | GSK3B (0.65) | GSK3BCHEK1CDK2CCNA2CCNA1 | |
| SCHEMBL13304928 | 0.81 | GSK3B (0.51) | GSK3BCHEK1CDK2CCNA2CCNA1 | |
| SCHEMBL13146493 | 0.81 | GSK3B (0.52) | GSK3BCHEK1CDK2CCNA2CCNA1 | |
| SCHEMBL13305036 | 0.81 | GSK3B (0.55) | GSK3BCHEK1CDK2CCNA2CCNA1 | |
| SCHEMBL14412770 | 0.80 | GSK3B (0.67) | GSK3BCHEK1CDK2CCNA2CCNA1 | |
| SCHEMBL13304821 | 0.79 | GSK3B (0.53) | GSK3BCHEK1CDK2CCNA2CCNA1 | |
| SCHEMBL13146196 | 0.78 | GSK3B (0.55) | GSK3BCDK2CCNA2CCNA1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | GSK3B 695/4885CHEK1 60/4885CDK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.